OBX-115

BIOLOGICAL2 trials

Sponsors

M.D. Anderson Cancer Center, Obsidian Therapeutics, Inc.

Conditions

Lung CancerMelanomaMetastatic Lung CancerMetastatic MelanomaMetastatic Non Small Cell Lung CancerNon Small Cell Lung CancerTumorTumor Skin

Phase 1

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Active, not recruitingNCT05470283

M.D. Anderson Cancer CenterMelanoma, Metastatic Melanoma, Tumor

Start: 2022-09-07End: 2027-04-01Updated: 2026-09-11

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

RecruitingNCT06060613

Obsidian Therapeutics, Inc.Lung Cancer, Melanoma, Metastatic Lung Cancer +4

Start: 2023-10-25End: 2029-06-30Target: 208Updated: 2026-07-16

Related Papers

OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mbIL15) in patients with advanced melanoma that has progressed on/after immune checkpoint inhibitors (ICI): Phase 2 results.

Journal of Clinical Oncology2026-05-28

Abstract LB-A010: Translational data validate OBX-115 mechanism of action: Impact of dosing on clinical outcome in advanced (adv) melanoma

Cancer Immunology Research2026-03-05

OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mbIL15) in patients (pts) with immune checkpoint inhibitor (ICI)–resistant advanced melanoma: Phase 1 results of the Agni-01 multicenter study.

Journal of Clinical Oncology2025-05-282 citations

OBX-115 engineered tumor-infiltrating lymphocytes (TIL) with regulatable membrane-bound IL15 (mbIL15): Translational data from a single-center phase 1 trial in patients (pts) with immune checkpoint inhibitor (ICI)–resistant advanced melanoma.

Journal of Clinical Oncology2025-05-28

Abstract CT244: Trial in progress: Phase 1/2 study of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced solid tumors

Cancer Research2025-04-251 citations

Abstract LB359: OBX-115 TIL from non-small cell lung cancer (NSCLC) are enriched for putative tumor-reactive, stem-like T cells with enhanced tumor cytotoxicity: Results from multimodal phenotyping analysis

Cancer Research2025-04-25

Recent Advancements in Cell-Based Therapies in Melanoma.

2024-09-124 citations

OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma.

Journal of Clinical Oncology2024-06-0119 citations

A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2024-06-015 citations

Abstract LB065: Tumor-infiltrating lymphocytes (TIL) engineered with regulatable membrane-bound IL15 (mbIL15) and LIGHT (TNFSF14) show enhanced efficacy in fibroblast-containing cold tumors

Cancer Research2024-04-052 citations

Abstract CT176: OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy induced deepening and durable responses without interleukin 2 (IL2) in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma

Cancer Research2024-04-051 citations

Abstract LB072: Tumor-infiltrating lymphocytes (TIL) engineered with membrane-bound IL15 (cytoTIL15 cells) exhibit pharmacologically regulatable signal transduction in cis and trans

Cancer Research2024-04-051 citations

Abstract CT285: Trial in progress: A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with immune checkpoint inhibitor (ICI)-resistant advanced or metastatic melanoma

Cancer Research2024-04-05

Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma

Journal for ImmunoTherapy of Cancer2024-02-0142 citations

348 TIL engineered with membrane-bound IL15 (cytoTIL15™) are enriched for tumor-associated antigen reactivity and demonstrate pharmacologically tunable expansion and persistence in the presence of TAA

Regular and Young Investigator Award Abstracts2023-10-31